03-23-06

CASE ON/4-32717A

IFW

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV727274625US
Express Mail Label Number

March 22, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
DE BONT ET AL.
INTERNATIONAL APPLICATION NO: PCT/EP03/11084
FILED: 7 OCTOBER 2003
U.S. APPLICATION NO: 10/530,452
35 USC §371 DATE: 9 SEPTEMBER 2005
FOR: TREATMENT OF AML

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed. GB 871753 and GB 1293565 are substantially equivalent to German patents DE 1 061 788 and DE 2021195.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898

Date: March 22, 2003

FORM PTO-1449 (REV. 7-85)
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32717A
APPLICATION NO.
10/530,452
APPLICANT
DE BONT ET AL.
FILING DATE
SEPTEMBER 9, 2005
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	2,960,504	11/15/60	Druey et al.			
	AB	3,753,988	8/21/73	Rodway et al.			
	AC	4,665,181	5/12/87	Thomas et al.			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM	*98 35958	8/20/98	WO			☐	☐
	AN	*02 41882	5/30/02	WO			☐	☐
	AO	*03 035047	5/1/03	WO			☐	☐
	AP	*03 022282	3/20/03	WO			☐	☐
	AQ	*03 059354	7/24/03	WO			☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	*Mesters R. M. et al., "Angiogenesis Bei Haematologischen Neoplasien," Onkologie, Vol. 24, No. Suppl. 5, pp. 75-80 (2001) (English abstract)
	AS	*Wood, "Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy," Medicina, Vol. 60, No. Suppl 2, pp. 41-47 (2000)
	AT	*Wood et al., "PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration," Cancer Research, Vol. 60, No. 8, p. 2178-2189 (2000)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. ON/4-32717A
APPLICATION NO. 10/530,452
APPLICANT DE BONT ET AL.
FILING DATE SEPTEMBER 9, 2005
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	BM	3-106875	5/7/91	JP (English translation)			☐	☐
	BN	3-106873	5/7/91	JP (English translation)			☐	☐
	BO	361,812	6/30/62	CH (English abstract)			☐	☐
	BP	07224067	8/22/95	JP (English abstract)			☐	☐
	BQ	3106872	5/7/91	JP (English abstract)			☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	*Lin et al., "The VEGF receptor tyrosine kinase inhibitor PTK787 inhibits proliferation and migration of multiple myeloma cells, and reduces paracrine-mediated responses to the bone marrow microenvironment," Blood, Vol. 98, No. 11, pp. 166A (2001)
	BS	*Traxler et al., "Tyrosine kinase inhibitors: from rational design to clinical trials," Medicinal Research Reviews, Vol. 21, No. 6, pp. 499-512 (2001)
	BT	*Roboz et al., "Phase I trial of PTK787/ZK 222584, a inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in acute myeloid leukemia and myelodysplastic syndrome," Blood, Vol. 100, No. 11, pp. Abstract No. 1308 (2002)

EXAMINER | **DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32717A
APPLICATION NO.
10/530,452
APPLICANT
DE BONT ET AL.
FILING DATE
SEPTEMBER 9, 2005
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	BM	3106874	5/7/91	JP (English Abstract)			☐	☐
	BN	516563	1/31/72	CH (English Abstract)			☐	☐
	BO	00 59509	10/12/00	WO			☐	☐
	BP	02 089772	11/14/02	WO			☐	☐
	BQ						☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	*Escribano et al., "Expression of the C-kit (CD117) molecule in normal and malignant hematopoiesis," Vol. 30, No. 5/6, pp. 459-466 (1998)
	BS	Watanabe et al., "4-benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5," J. Med. Chem., Vol. 41, pp. 3367-3372 (1998)
	BT	O'Reilly et al., "Angiostatin induces and sustains dormancy of human primary tumors in mice," Nature Medicine, Vol. 2, No. 6, pp. 689-692 (1996)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. ON/4-32717A
APPLICATION NO. 10/530,452
APPLICANT DE BONT ET AL.
FILING DATE SEPTEMBER 9, 2005
Group

EXAMINER INITIAL		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
	DA	Wagaw et al., "The synthesis of aminopyridines: a method employing palladium-catalyzed carbon-nitrogen bond formation," J. Org. Chem., Vol. 61, pp. 7240-7241 (1996)
	DB	Haworth et al., "Synthetic antimalarials, Part XXVII. Some derivatives of phthalazine, quinoxaline, and isoQuinoline," J. Chem. Soc., Vol. 25, pp. 777-782 (1948)
	DC	Yamaguchi et al., "Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-imidazolyl)alkyl]-1(2H)-phthalazinones," J. Med. Chem., Vol 36, pp. 4052-4060 (1993)
	DD	Seed, "Angiogenesis inhibition as a drug target for disease: an update," Exp. Opin. Invest. Drugs, Vol. 5, No. 12 pp. 1617-1637 (1996)
	DE	Hennequin et al., "Design and structure-activity relatinship of a new class of potent VEGF receptor tyrosine kinase inhibitors," J. Med. Chem. Vol. 42, pp. 5369-5389 (1999)
	DF	Ishihara et al., "Pharmacological Characterization of a novel, potent and selective phospodiesterase 5 inhibitor, E4010," Jpn. J. Pharmacol., Vol. 76, p. 175ff. (1998)
	DG	Chemical Abstracts, No. 115-256197a, Vol. 115, No. 23 (1991)
	DH	Schuler et al., "The relation of the hypotensive and reserpine-antagonizing effects of hydrazine derivaties to enzyme- and metal-catalysis ofbiogenic amines in vitro," Arch. Int. Pharacodyn., CXXVIII, 3-4, pp. 431-468 (1960); Abstract CA 55:11654 (1961)
	DI	Drevs et al., "Effects of PTK787/ZK 222584, a specific vascular endothelial growth factor (VEGF)-receptor tyrosine kinase inhibitor, on primary tumor, metastasis, vessel density and blood flow in a murine renal cell carcinoma," pp. 1-22
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32717A
APPLICATION NO.
10/530,452
APPLICANT
DE BONT ET AL.
FILING DATE
SEPTEMBER 9, 2005
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	BM	871753	6/28/61	GB			☐	☐
	BN	0722936	7/24/96	EP			☐	☐
	BO	1293565	6/18/72	GB			☐	☐
	BP	1 133 406	11/13/68	GB			☐	☐
	BQ	97 26258	7/24/97	WO			☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	
	BS	
	BT	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. ON/4-32717A
APPLICATION NO. 10/530,452
APPLICANT DE BONT ET AL.
FILING DATE SEPTEMBER 9, 2005
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	BM	97 40020	10/30/97	WO (abstract only)			☐	☐
	BN	0600831	6/8/94	EP (abstract only)			☐	☐
	BO						☐	☐
	BP						☐	☐
	BQ						☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	
	BS	
	BT	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.